Pipeline Watch: Phase III Read-Outs For Ozanimod, Olaparib And Sapacitabine
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
You may also be interested in...
Two-week treatment data comparing the investigational echinocandin antifungal with caspofungin shows trend toward better cure rate with similar efficacy. Cidara plans Phase III trials for treatment and prevention of difficult-to-treat infections.
With three biopharma initial public offerings in April, the second quarter is on track to beat the first quarter's total of five IPOs – three in January and two in March – and several more are in the queue.
La Jolla Pharmaceutical grossed $125m, Inspyr Therapeutics signs a deal to raise up to $100m, Ionis's Akcea makes $100m IPO plans, and $64m in cash for SutroVax tops recent venture capital rounds.